retatrutide fda status CT Health News | Doctors are warning patients against using unapproved versions of retatrutide, an experimental Eli Lilly weight loss drug still in clinical Retatrutide FDA Approval Status 2026:

Updated timeline: May 2026: TRIUMPH-1 Phase 3 topline results announced Late 20262027: Remaining TRIUMPH trials complete

95% CI, 0.380.99), as well as a decrease in the rate of MACE by 26% (79)

Compare category Quick sourcing answer Identity CAS 2381089-83-2

Phase 2 reported no increase in serious cardiovascular events

The researchers extrapolated that would translate to more than two million Canadian adults

General best-practice guidance consistent with NHS and professional body recommendations supports regular resistance exercise and adequate dietary protein intake to help preserve muscle tissue during weight management